HRP20110808T1 - Derivati piridazina - Google Patents
Derivati piridazina Download PDFInfo
- Publication number
- HRP20110808T1 HRP20110808T1 HR20110808T HRP20110808T HRP20110808T1 HR P20110808 T1 HRP20110808 T1 HR P20110808T1 HR 20110808 T HR20110808 T HR 20110808T HR P20110808 T HRP20110808 T HR P20110808T HR P20110808 T1 HRP20110808 T1 HR P20110808T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- undeca
- triene
- diazatricyclo
- trifluoromethyl
- Prior art date
Links
- 150000004892 pyridazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 26
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 16
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 11
- 125000001424 substituent group Chemical group 0.000 claims abstract 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract 9
- 150000002367 halogens Chemical class 0.000 claims abstract 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 7
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims abstract 6
- 125000003118 aryl group Chemical group 0.000 claims abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 6
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 4
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- PHPAUSAAOFTBEN-UHFFFAOYSA-N 3-(furan-2-yl)-5-methyl-5,6,7,8-tetrahydroquinoline Chemical compound O1C(=CC=C1)C=1C=NC=2CCCC(C=2C=1)C PHPAUSAAOFTBEN-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- XQQUSVHISAVPIV-UHFFFAOYSA-N undeca-2,4,6-triene Chemical compound CCCCC=CC=CC=CC XQQUSVHISAVPIV-UHFFFAOYSA-N 0.000 claims 17
- -1 trifluoromethoxy, benzyl Chemical group 0.000 claims 10
- 238000011321 prophylaxis Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- MBJPIDLEZOJGBU-UHFFFAOYSA-N 3-[2-(trifluoromethyl)phenyl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound FC(F)(F)C1=CC=CC=C1C(N=N1)=CC2=C1CCCCCC2 MBJPIDLEZOJGBU-UHFFFAOYSA-N 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- PDJJXZPVBDQSFQ-SCLBCKFNSA-N (1S,8R)-5-(2-chlorophenyl)-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CC=C1Cl PDJJXZPVBDQSFQ-SCLBCKFNSA-N 0.000 claims 2
- RILPEIRRUNHXLU-SCLBCKFNSA-N (1S,8R)-5-(2-fluorophenyl)-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CC=C1F RILPEIRRUNHXLU-SCLBCKFNSA-N 0.000 claims 2
- MLKBOTMGWYAPRL-HRAATJIYSA-N (1S,8R)-5-[1-(4-chlorophenyl)-5-(trifluoromethyl)pyrazol-4-yl]-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C(=C1C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 MLKBOTMGWYAPRL-HRAATJIYSA-N 0.000 claims 2
- DLZSNWWSRKMQJG-SCLBCKFNSA-N (1S,8R)-5-[4-fluoro-2-(trifluoromethyl)phenyl]-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=C(F)C=C1C(F)(F)F DLZSNWWSRKMQJG-SCLBCKFNSA-N 0.000 claims 2
- BSFLCKBWXRSZEJ-ABAIWWIYSA-N (1r,8s)-5-cyclopropyl-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2(7),3,5-triene Chemical compound C1([C@]2(C)CC[C@H](C1=C1)C2(C)C)=NN=C1C1CC1 BSFLCKBWXRSZEJ-ABAIWWIYSA-N 0.000 claims 2
- NZAVTOUJCGXJBB-MEDUHNTESA-N (1s,8r)-1,11,11-trimethyl-5-(1-methyl-cyclopropyl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1(C)CC1 NZAVTOUJCGXJBB-MEDUHNTESA-N 0.000 claims 2
- PMZMCJRAUVPQIB-IINYFYTJSA-N (1s,8r)-1,11,11-trimethyl-5-(1-trifluoromethyl-cyclopropyl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1(C(F)(F)F)CC1 PMZMCJRAUVPQIB-IINYFYTJSA-N 0.000 claims 2
- KCTJBEYFJDOJCQ-MEDUHNTESA-N (1s,8r)-5-cyclopropyl-1,6,11,11-tetramethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1C)(C2(C)C)[H])C)=NN=C1C1CC1 KCTJBEYFJDOJCQ-MEDUHNTESA-N 0.000 claims 2
- DFAOHCAPALRYPX-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)-5-(trifluoromethyl)pyrazol-4-yl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC(F)(F)C1=C(C=2N=NC=3CCCCCC=3C=2)C=NN1C1=CC=C(Cl)C=C1 DFAOHCAPALRYPX-UHFFFAOYSA-N 0.000 claims 2
- OGYQWVIQTKAHAJ-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclobutyl]-5,6,7,8-tetrahydroquinoline Chemical compound ClC1=CC=C(C=C1)C1(CCC1)C=1C=NC=2CCCCC=2C=1 OGYQWVIQTKAHAJ-UHFFFAOYSA-N 0.000 claims 2
- SLXGQKYJDXUWGU-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclopropyl]-5,6,7,8-tetrahydroquinoline Chemical compound ClC1=CC=C(C=C1)C1(CC1)C=1C=NC=2CCCCC=2C=1 SLXGQKYJDXUWGU-UHFFFAOYSA-N 0.000 claims 2
- IKSMIDXNVKGZRN-UHFFFAOYSA-N 3-[1-methyl-5-(trifluoromethyl)pyrazol-4-yl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound CN1N=CC(C=2N=NC=3CCCCCC=3C=2)=C1C(F)(F)F IKSMIDXNVKGZRN-UHFFFAOYSA-N 0.000 claims 2
- GAGNNVQLQFWNLK-UHFFFAOYSA-N 3-[2-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC(F)(F)C1=CC=CC=C1C(N=N1)=CC2=C1CCCCC2 GAGNNVQLQFWNLK-UHFFFAOYSA-N 0.000 claims 2
- IBWAOMQRILTGDK-UHFFFAOYSA-N 3-[3-fluoro-2-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC1=CC=CC(C=2N=NC=3CCCCCC=3C=2)=C1C(F)(F)F IBWAOMQRILTGDK-UHFFFAOYSA-N 0.000 claims 2
- BNUXSTCXPYBDCM-UHFFFAOYSA-N 3-[4-fluoro-2-(trifluoromethyl)phenyl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound FC(F)(F)C1=CC(F)=CC=C1C(N=N1)=CC2=C1CCCCCC2 BNUXSTCXPYBDCM-UHFFFAOYSA-N 0.000 claims 2
- HENUEMRGIITXES-UHFFFAOYSA-N 3-[4-fluoro-2-(trifluoromethyl)phenyl]-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC=C(F)C=C1C(F)(F)F HENUEMRGIITXES-UHFFFAOYSA-N 0.000 claims 2
- VCLDMTPAGJQYSO-UHFFFAOYSA-N 3-[4-fluoro-2-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC(F)(F)C1=CC(F)=CC=C1C(N=N1)=CC2=C1CCCCC2 VCLDMTPAGJQYSO-UHFFFAOYSA-N 0.000 claims 2
- SFQHRSQDLRPFFI-UHFFFAOYSA-N 3-[5-fluoro-2-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC1=CC=C(C(F)(F)F)C(C=2N=NC=3CCCCCC=3C=2)=C1 SFQHRSQDLRPFFI-UHFFFAOYSA-N 0.000 claims 2
- RJVYTPDZNUXMGP-UHFFFAOYSA-N C1=CC(F)=CC=C1N1C(C(F)(F)F)=C(C=2N=NC=3C4CCC(C4)C=3C=2)C=N1 Chemical compound C1=CC(F)=CC=C1N1C(C(F)(F)F)=C(C=2N=NC=3C4CCC(C4)C=3C=2)C=N1 RJVYTPDZNUXMGP-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- UNANXMDFHAWWFR-IERDGZPVSA-N (1R,8S)-1,11,11-trimethyl-5-[1-phenyl-5-(trifluoromethyl)pyrazol-4-yl]-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@@]2(CC[C@](C1=C1)(C2(C)C)[H])C)=NN=C1C(=C1C(F)(F)F)C=NN1C1=CC=CC=C1 UNANXMDFHAWWFR-IERDGZPVSA-N 0.000 claims 1
- CJPVHTXDHOJGKB-ACJLOTCBSA-N (1R,8S)-1,11,11-trimethyl-5-[2-(trifluoromethyl)phenyl]-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@@]2(CC[C@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CC=C1C(F)(F)F CJPVHTXDHOJGKB-ACJLOTCBSA-N 0.000 claims 1
- HPYQHSQALBVNAD-KDOFPFPSSA-N (1R,8S)-1,11,11-trimethyl-5-[4-(trifluoromethyl)phenyl]-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@@]2(CC[C@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=C(C(F)(F)F)C=C1 HPYQHSQALBVNAD-KDOFPFPSSA-N 0.000 claims 1
- CFJKJUIOEZBBFK-KDOFPFPSSA-N (1R,8S)-1,11,11-trimethyl-5-phenyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@@]2(CC[C@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CC=C1 CFJKJUIOEZBBFK-KDOFPFPSSA-N 0.000 claims 1
- PDJJXZPVBDQSFQ-ACJLOTCBSA-N (1R,8S)-5-(2-chlorophenyl)-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@@]2(CC[C@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CC=C1Cl PDJJXZPVBDQSFQ-ACJLOTCBSA-N 0.000 claims 1
- MLKBOTMGWYAPRL-IERDGZPVSA-N (1R,8S)-5-[1-(4-chlorophenyl)-5-(trifluoromethyl)pyrazol-4-yl]-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@@]2(CC[C@](C1=C1)(C2(C)C)[H])C)=NN=C1C(=C1C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 MLKBOTMGWYAPRL-IERDGZPVSA-N 0.000 claims 1
- UVSIKXDUMSJDCC-ZUZCIYMTSA-N (1S,8R)-1,11,11-trimethyl-5-[5-(trifluoromethyl)-1H-pyrazol-4-yl]-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CNN=C1C(F)(F)F UVSIKXDUMSJDCC-ZUZCIYMTSA-N 0.000 claims 1
- CFJKJUIOEZBBFK-KBXCAEBGSA-N (1S,8R)-1,11,11-trimethyl-5-phenyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CC=C1 CFJKJUIOEZBBFK-KBXCAEBGSA-N 0.000 claims 1
- YJRDTGUWXRCSJV-SCLBCKFNSA-N (1S,8R)-5-(2,4-difluorophenyl)-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=C(F)C=C1F YJRDTGUWXRCSJV-SCLBCKFNSA-N 0.000 claims 1
- NPUDTAUWJBJKSQ-SCLBCKFNSA-N (1S,8R)-5-(2,5-difluorophenyl)-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC(F)=CC=C1F NPUDTAUWJBJKSQ-SCLBCKFNSA-N 0.000 claims 1
- ARZGILPCNVVXTB-KBXCAEBGSA-N (1S,8R)-5-(4-fluorophenyl)-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=C(F)C=C1 ARZGILPCNVVXTB-KBXCAEBGSA-N 0.000 claims 1
- WDPPYYGEKVCBGS-LAUBAEHRSA-N (1S,8R)-5-[1-(4-chlorophenyl)cyclobutyl]-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1(C=2C=CC(Cl)=CC=2)CCC1 WDPPYYGEKVCBGS-LAUBAEHRSA-N 0.000 claims 1
- AQRTUURAGVCSCO-OXJNMPFZSA-N (1S,8R)-5-[1-(4-chlorophenyl)cyclopropyl]-1,11,11-trimethyl-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1(C=2C=CC(Cl)=CC=2)CC1 AQRTUURAGVCSCO-OXJNMPFZSA-N 0.000 claims 1
- ZPPVCKWSPXMEEZ-YVEFUNNKSA-N (1s,8r)-1,11,11-trimethyl-5-(1-methyl-1h-pyrrol-2-yl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CN1C ZPPVCKWSPXMEEZ-YVEFUNNKSA-N 0.000 claims 1
- WWOOCLOJCFWIRX-KSFYIVLOSA-N (1s,8r)-1,11,11-trimethyl-5-(4-methyl-2-phenyl-thiazol-5-yl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C(=C(N=1)C)SC=1C1=CC=CC=C1 WWOOCLOJCFWIRX-KSFYIVLOSA-N 0.000 claims 1
- NIGNFKCJAHPNDS-WMZHIEFXSA-N (1s,8r)-5-(1-benzyl-3-methyl-1h-pyrazol-4-yl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C(C(=N1)C)=CN1CC1=CC=CC=C1 NIGNFKCJAHPNDS-WMZHIEFXSA-N 0.000 claims 1
- JSFWJMLBYRXYTM-WMZHIEFXSA-N (1s,8r)-5-(1-benzyl-5-methyl-1h-pyrazol-4-yl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C(=C1C)C=NN1CC1=CC=CC=C1 JSFWJMLBYRXYTM-WMZHIEFXSA-N 0.000 claims 1
- AAHNUSJRWRCSQP-KSFYIVLOSA-N (1s,8r)-5-(1-tert-butyl-5-cyclopropyl-1h-pyrazol-4-yl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C=1C=NN(C(C)(C)C)C=1C1CC1 AAHNUSJRWRCSQP-KSFYIVLOSA-N 0.000 claims 1
- RAHOZOLUTBRBDJ-MGPUTAFESA-N (1s,8r)-5-(1-tert-butyl-5-methyl-1h-pyrazol-4-yl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C=1C=NN(C(C)(C)C)C=1C RAHOZOLUTBRBDJ-MGPUTAFESA-N 0.000 claims 1
- DLHJMRPAQVMPRP-UQBPGWFLSA-N (1s,8r)-5-(1-tert-butyl-5-phenyl-1h-pyrazol-4-yl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C=1C=NN(C(C)(C)C)C=1C1=CC=CC=C1 DLHJMRPAQVMPRP-UQBPGWFLSA-N 0.000 claims 1
- VLQIGPGZCFEJHH-ORAYPTAESA-N (1s,8r)-5-(1-tert-butyl-5-trifluoromethyl-1h-pyrazol-4-yl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C=1C=NN(C(C)(C)C)C=1C(F)(F)F VLQIGPGZCFEJHH-ORAYPTAESA-N 0.000 claims 1
- IURFMAQETVXQEZ-BBATYDOGSA-N (1s,8r)-5-(2-chloro-4,5-difluoro-phenyl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC(F)=C(F)C=C1Cl IURFMAQETVXQEZ-BBATYDOGSA-N 0.000 claims 1
- JTZBVZBAKLCVBD-SCLBCKFNSA-N (1s,8r)-5-(2-chloro-4-fluoro-phenyl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=C(F)C=C1Cl JTZBVZBAKLCVBD-SCLBCKFNSA-N 0.000 claims 1
- WCKBJVZUDIXCKK-IFXJQAMLSA-N (1s,8r)-5-(2-methoxy-phenyl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC=CC=C1OC WCKBJVZUDIXCKK-IFXJQAMLSA-N 0.000 claims 1
- UZFRFJSSMDTRRC-MNOVXSKESA-N (1s,8r)-5-(4-chloro-2-methyl-phenyl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2(7),3,5-triene Chemical compound CC1=CC(Cl)=CC=C1C(N=N1)=CC2=C1[C@H]1CC[C@@H]2C1 UZFRFJSSMDTRRC-MNOVXSKESA-N 0.000 claims 1
- RHGCNDMOMNWJCG-QFBILLFUSA-N (1s,8r)-5-(4-chloro-benzyl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1CC1=CC=C(Cl)C=C1 RHGCNDMOMNWJCG-QFBILLFUSA-N 0.000 claims 1
- YHGDQNMNYYYBRU-IFXJQAMLSA-N (1s,8r)-5-(5-cyclopropyl-1-methyl-1h-pyrazol-4-yl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C=1C=NN(C)C=1C1CC1 YHGDQNMNYYYBRU-IFXJQAMLSA-N 0.000 claims 1
- XMZSGEVTTWTKDW-IFXJQAMLSA-N (1s,8r)-5-(5-fluoro-2-methoxy-phenyl)-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC(F)=CC=C1OC XMZSGEVTTWTKDW-IFXJQAMLSA-N 0.000 claims 1
- LBHNODZSYIBSBL-BLLLJJGKSA-N (1s,8r)-5-cyclobutyl-1,11,11-trimethyl-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1CCC1 LBHNODZSYIBSBL-BLLLJJGKSA-N 0.000 claims 1
- HEEDOIRIGXFMGG-UHFFFAOYSA-N (1sr,8rs)-5-(1-methyl-3-trifluoromethyl-1h-pyrazol-4-yl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound FC(F)(F)C1=NN(C)C=C1C(N=N1)=CC2=C1C1CCC2C1 HEEDOIRIGXFMGG-UHFFFAOYSA-N 0.000 claims 1
- LJQSKNRPNCQFDO-UHFFFAOYSA-N (1sr,8rs)-5-(1-tert-butyl-5-cyclopropyl-1h-pyrazol-4-yl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound CC(C)(C)N1N=CC(C=2N=NC=3C4CCC(C4)C=3C=2)=C1C1CC1 LJQSKNRPNCQFDO-UHFFFAOYSA-N 0.000 claims 1
- XPIHRDLBMAVELS-UHFFFAOYSA-N (1sr,8rs)-5-(1-tert-butyl-5-methyl-1h-pyrazol-4-yl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound C1=NN(C(C)(C)C)C(C)=C1C(N=N1)=CC2=C1C1CCC2C1 XPIHRDLBMAVELS-UHFFFAOYSA-N 0.000 claims 1
- QRPQKSMUTPVPMB-UHFFFAOYSA-N (1sr,8rs)-5-(1-tert-butyl-5-trifluoromethyl-1h-pyrazol-4-yl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound CC(C)(C)N1N=CC(C=2N=NC=3C4CCC(C4)C=3C=2)=C1C(F)(F)F QRPQKSMUTPVPMB-UHFFFAOYSA-N 0.000 claims 1
- JRECRNVSPMMNIO-UHFFFAOYSA-N (1sr,8rs)-5-(5-chloro-2-trifluoromethyl-phenyl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2(7),3,5-triene Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1C(N=N1)=CC2=C1C1CCC2C1 JRECRNVSPMMNIO-UHFFFAOYSA-N 0.000 claims 1
- XRASAQOFEIVBIQ-UHFFFAOYSA-N (1sr,8rs)-5-(5-cyclopropyl-1-methyl-1h-pyrazol-4-yl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound CN1N=CC(C=2N=NC=3C4CCC(C4)C=3C=2)=C1C1CC1 XRASAQOFEIVBIQ-UHFFFAOYSA-N 0.000 claims 1
- LOYJSKMQJQLAIC-UHFFFAOYSA-N (1sr,8rs)-5-(5-fluoro-2-trifluoromethyl-phenyl)-3,4-diaza-tricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound FC1=CC=C(C(F)(F)F)C(C=2N=NC=3C4CCC(C4)C=3C=2)=C1 LOYJSKMQJQLAIC-UHFFFAOYSA-N 0.000 claims 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 claims 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 claims 1
- LJFFYOSJMUDELQ-UHFFFAOYSA-N 3,4-dicyclopropyl-6-(1-phenyl-5-propylpyrazol-4-yl)pyridazine Chemical compound CCCC1=C(C=2N=NC(=C(C3CC3)C=2)C2CC2)C=NN1C1=CC=CC=C1 LJFFYOSJMUDELQ-UHFFFAOYSA-N 0.000 claims 1
- NLCAKMPPYCOBPP-UHFFFAOYSA-N 3,4-dicyclopropyl-6-(5-methyl-1-phenylpyrazol-4-yl)pyridazine Chemical compound CC1=C(C=2N=NC(=C(C3CC3)C=2)C2CC2)C=NN1C1=CC=CC=C1 NLCAKMPPYCOBPP-UHFFFAOYSA-N 0.000 claims 1
- XKCYPWAEKCRTTG-UHFFFAOYSA-N 3,4-dicyclopropyl-6-[2-(trifluoromethyl)phenyl]pyridazine Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC(C2CC2)=C(C2CC2)N=N1 XKCYPWAEKCRTTG-UHFFFAOYSA-N 0.000 claims 1
- OEKDWUFPMOTMSY-UHFFFAOYSA-N 3-(1-adamantyl)-5,6,7,8-tetrahydroquinoline Chemical compound C12(CC3CC(CC(C1)C3)C2)C=1C=NC=2CCCCC=2C=1 OEKDWUFPMOTMSY-UHFFFAOYSA-N 0.000 claims 1
- STPURMQHFSMFAI-UHFFFAOYSA-N 3-(1-methylcyclopropyl)-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound C=1C=2CCCCCCC=2N=NC=1C1(C)CC1 STPURMQHFSMFAI-UHFFFAOYSA-N 0.000 claims 1
- TWGAIFZQQKQHKE-UHFFFAOYSA-N 3-(1-methylpyrrol-2-yl)-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound CN1C=CC=C1C(N=N1)=CC2=C1CCCCCC2 TWGAIFZQQKQHKE-UHFFFAOYSA-N 0.000 claims 1
- SGKDHNWWMCEHRU-UHFFFAOYSA-N 3-(1-methylpyrrol-2-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound CN1C=CC=C1C(N=N1)=CC2=C1CCCCC2 SGKDHNWWMCEHRU-UHFFFAOYSA-N 0.000 claims 1
- JKABPKMIPZRKFB-UHFFFAOYSA-N 3-(1-phenyl-5-propylpyrazol-4-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound CCCC1=C(C=2N=NC=3CCCCCC=3C=2)C=NN1C1=CC=CC=C1 JKABPKMIPZRKFB-UHFFFAOYSA-N 0.000 claims 1
- QXTCZLIJOHUOBV-UHFFFAOYSA-N 3-(1-tert-butyl-5-methylpyrazol-4-yl)-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound C1=NN(C(C)(C)C)C(C)=C1C(N=N1)=CC2=C1CC(C)(C)C2 QXTCZLIJOHUOBV-UHFFFAOYSA-N 0.000 claims 1
- LJDLAGOXZWYSRB-UHFFFAOYSA-N 3-(2,3-dimethylphenyl)-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound CC1=CC=CC(C=2N=NC=3CC(C)(C)CC=3C=2)=C1C LJDLAGOXZWYSRB-UHFFFAOYSA-N 0.000 claims 1
- KRWLGRGIGKNXPW-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC=C(F)C=C1F KRWLGRGIGKNXPW-UHFFFAOYSA-N 0.000 claims 1
- YHNIBESRQHCDCW-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC1=CC(F)=CC=C1C(N=N1)=CC2=C1CCCCC2 YHNIBESRQHCDCW-UHFFFAOYSA-N 0.000 claims 1
- OUGLBDIPYWMVEN-UHFFFAOYSA-N 3-(2,5-dichlorophenyl)-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC(Cl)=CC=C1Cl OUGLBDIPYWMVEN-UHFFFAOYSA-N 0.000 claims 1
- NEAUXGBHPCVIPS-UHFFFAOYSA-N 3-(2,5-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC1=CC=C(F)C(C=2N=NC=3CCCCCC=3C=2)=C1 NEAUXGBHPCVIPS-UHFFFAOYSA-N 0.000 claims 1
- LVVLCZNERMMNAD-UHFFFAOYSA-N 3-(2-chlorophenyl)-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC=CC=C1Cl LVVLCZNERMMNAD-UHFFFAOYSA-N 0.000 claims 1
- VVOUWUIJCYNGAK-UHFFFAOYSA-N 3-(2-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound FC1=CC=CC=C1C(N=N1)=CC2=C1CCCCCC2 VVOUWUIJCYNGAK-UHFFFAOYSA-N 0.000 claims 1
- UDANGMIVOAMLMF-UHFFFAOYSA-N 3-(2-fluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound FC1=CC=CC=C1C(N=N1)=CC2=C1CCCCC2 UDANGMIVOAMLMF-UHFFFAOYSA-N 0.000 claims 1
- SKXBFBSECONGDT-UHFFFAOYSA-N 3-(2-methoxyphenyl)-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound COC1=CC=CC=C1C(N=N1)=CC2=C1CCCCCC2 SKXBFBSECONGDT-UHFFFAOYSA-N 0.000 claims 1
- KCDIZJSDHSESFC-UHFFFAOYSA-N 3-(2-methoxyphenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound COC1=CC=CC=C1C(N=N1)=CC2=C1CCCCC2 KCDIZJSDHSESFC-UHFFFAOYSA-N 0.000 claims 1
- FGABAZYTRIKFTD-UHFFFAOYSA-N 3-(2-methylphenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound CC1=CC=CC=C1C(N=N1)=CC2=C1CCCCC2 FGABAZYTRIKFTD-UHFFFAOYSA-N 0.000 claims 1
- ZOHLNQWLEYRRMC-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound CC1=CC(Cl)=CC=C1C(N=N1)=CC2=C1CCCCCC2 ZOHLNQWLEYRRMC-UHFFFAOYSA-N 0.000 claims 1
- JQCRMLFEXQYBQX-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound CC1=CC(Cl)=CC=C1C(N=N1)=CC2=C1CCCCC2 JQCRMLFEXQYBQX-UHFFFAOYSA-N 0.000 claims 1
- NBWWFVKCXFMYBD-UHFFFAOYSA-N 3-(5-cyclopropyl-1-methylpyrazol-4-yl)-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound CN1N=CC(C=2N=NC=3CC(C)(C)CC=3C=2)=C1C1CC1 NBWWFVKCXFMYBD-UHFFFAOYSA-N 0.000 claims 1
- CJZGIAYNILOBAK-UHFFFAOYSA-N 3-(5-methyl-1-phenylpyrazol-4-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound CC1=C(C=2N=NC=3CCCCCC=3C=2)C=NN1C1=CC=CC=C1 CJZGIAYNILOBAK-UHFFFAOYSA-N 0.000 claims 1
- YMLWRMMONYGXNZ-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclobutyl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound C1=CC(Cl)=CC=C1C1(C=2N=NC=3CCCCCCC=3C=2)CCC1 YMLWRMMONYGXNZ-UHFFFAOYSA-N 0.000 claims 1
- BDXTXNWLAMXKNK-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclobutyl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound C1=CC(Cl)=CC=C1C1(C=2N=NC=3CCCCCC=3C=2)CCC1 BDXTXNWLAMXKNK-UHFFFAOYSA-N 0.000 claims 1
- SGUSZGADIKCEFY-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclopropyl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound C1=CC(Cl)=CC=C1C1(C=2N=NC=3CCCCCCC=3C=2)CC1 SGUSZGADIKCEFY-UHFFFAOYSA-N 0.000 claims 1
- JWYCFLJCGANJTO-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclopropyl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound C1=CC(Cl)=CC=C1C1(C=2N=NC=3CCCCCC=3C=2)CC1 JWYCFLJCGANJTO-UHFFFAOYSA-N 0.000 claims 1
- NMZIGSYJQHHEIJ-UHFFFAOYSA-N 3-[1-(4-fluorophenyl)-5-(trifluoromethyl)pyrazol-4-yl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound C1=CC(F)=CC=C1N1C(C(F)(F)F)=C(C=2N=NC=3CCCCCCC=3C=2)C=N1 NMZIGSYJQHHEIJ-UHFFFAOYSA-N 0.000 claims 1
- DQOUWKCAVWEWCV-UHFFFAOYSA-N 3-[1-(4-fluorophenyl)-5-(trifluoromethyl)pyrazol-4-yl]-6,7,8,9-tetrahydro-5h-cyclohepta[c]pyridazine Chemical compound C1=CC(F)=CC=C1N1C(C(F)(F)F)=C(C=2N=NC=3CCCCCC=3C=2)C=N1 DQOUWKCAVWEWCV-UHFFFAOYSA-N 0.000 claims 1
- VEXDQKRQSDCWBF-UHFFFAOYSA-N 3-[1-phenyl-5-(trifluoromethyl)pyrazol-4-yl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound FC(F)(F)C1=C(C=2N=NC=3CCCCCCC=3C=2)C=NN1C1=CC=CC=C1 VEXDQKRQSDCWBF-UHFFFAOYSA-N 0.000 claims 1
- SWHSVGXZYYKPAW-UHFFFAOYSA-N 3-[1-phenyl-5-(trifluoromethyl)pyrazol-4-yl]-5,6,7,8-tetrahydroquinoline Chemical compound C1(=CC=CC=C1)N1N=CC(=C1C(F)(F)F)C=1C=NC=2CCCCC=2C=1 SWHSVGXZYYKPAW-UHFFFAOYSA-N 0.000 claims 1
- ZZUFDLTWZMLLFA-UHFFFAOYSA-N 3-[1-tert-butyl-5-(trifluoromethyl)pyrazol-4-yl]-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound CC(C)(C)N1N=CC(C=2N=NC=3CC(C)(C)CC=3C=2)=C1C(F)(F)F ZZUFDLTWZMLLFA-UHFFFAOYSA-N 0.000 claims 1
- NEBZKZVDWBBARI-UHFFFAOYSA-N 3-[3-fluoro-2-(trifluoromethyl)phenyl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound FC1=CC=CC(C=2N=NC=3CCCCCCC=3C=2)=C1C(F)(F)F NEBZKZVDWBBARI-UHFFFAOYSA-N 0.000 claims 1
- RBBFCCQQSBSAFW-UHFFFAOYSA-N 3-[3-fluoro-2-(trifluoromethyl)phenyl]-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC=CC(F)=C1C(F)(F)F RBBFCCQQSBSAFW-UHFFFAOYSA-N 0.000 claims 1
- FOJOJQCJVJNXCW-UHFFFAOYSA-N 3-[5-(trifluoromethyl)-1h-pyrazol-4-yl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound N1N=CC(C=2N=NC=3CCCCCCC=3C=2)=C1C(F)(F)F FOJOJQCJVJNXCW-UHFFFAOYSA-N 0.000 claims 1
- XPANNJIAZXESQN-UHFFFAOYSA-N 3-[5-chloro-2-(trifluoromethyl)phenyl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1C(N=N1)=CC2=C1CCCCCC2 XPANNJIAZXESQN-UHFFFAOYSA-N 0.000 claims 1
- VNZDEBFUIQOTAI-UHFFFAOYSA-N 3-[5-chloro-2-(trifluoromethyl)phenyl]-6,6-dimethyl-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC(Cl)=CC=C1C(F)(F)F VNZDEBFUIQOTAI-UHFFFAOYSA-N 0.000 claims 1
- NCLYZGULRJEYPR-UHFFFAOYSA-N 3-[5-fluoro-2-(trifluoromethyl)phenyl]-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound FC1=CC=C(C(F)(F)F)C(C=2N=NC=3CCCCCCC=3C=2)=C1 NCLYZGULRJEYPR-UHFFFAOYSA-N 0.000 claims 1
- BDSJACWZLORSLP-UHFFFAOYSA-N 3-cyclopropyl-5,6,7,8,9,10-hexahydrocycloocta[c]pyridazine Chemical compound C1CC1C(N=N1)=CC2=C1CCCCCC2 BDSJACWZLORSLP-UHFFFAOYSA-N 0.000 claims 1
- AAOIGRROIMRONS-UHFFFAOYSA-N 5-(5,6,7,8,9,10-hexahydrocycloocta[c]pyridazin-3-yl)-4-methyl-2-phenyl-1,3-thiazole Chemical compound S1C(C=2N=NC=3CCCCCCC=3C=2)=C(C)N=C1C1=CC=CC=C1 AAOIGRROIMRONS-UHFFFAOYSA-N 0.000 claims 1
- DXLGICXJRYSPHH-UHFFFAOYSA-N 5-[4-fluoro-2-(trifluoromethyl)phenyl]-3,4-diazatricyclo[6.2.1.02,7]undeca-2,4,6-triene Chemical compound FC(F)(F)C1=CC(F)=CC=C1C(N=N1)=CC2=C1C1CCC2C1 DXLGICXJRYSPHH-UHFFFAOYSA-N 0.000 claims 1
- YZJZMUWGFGUZTJ-UHFFFAOYSA-N 6,6-dimethyl-3-[2-(trifluoromethoxy)phenyl]-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC=CC=C1OC(F)(F)F YZJZMUWGFGUZTJ-UHFFFAOYSA-N 0.000 claims 1
- FCJGXIOCBBQSDL-UHFFFAOYSA-N 6,6-dimethyl-3-[2-(trifluoromethyl)phenyl]-5,7-dihydrocyclopenta[c]pyridazine Chemical compound N=1N=C2CC(C)(C)CC2=CC=1C1=CC=CC=C1C(F)(F)F FCJGXIOCBBQSDL-UHFFFAOYSA-N 0.000 claims 1
- JEUYHKHUYDVGDC-UHFFFAOYSA-N 6-[1-(4-chlorophenyl)cyclobutyl]-3,4-dicyclopropylpyridazine Chemical compound C1=CC(Cl)=CC=C1C1(C=2N=NC(=C(C3CC3)C=2)C2CC2)CCC1 JEUYHKHUYDVGDC-UHFFFAOYSA-N 0.000 claims 1
- MYRUFMHJDOOJRE-UHFFFAOYSA-N 6-[1-(4-chlorophenyl)cyclopropyl]-3,4-dicyclopropylpyridazine Chemical compound C1=CC(Cl)=CC=C1C1(C=2N=NC(=C(C3CC3)C=2)C2CC2)CC1 MYRUFMHJDOOJRE-UHFFFAOYSA-N 0.000 claims 1
- UCJPHVSPOPXDQD-YCRPNKLZSA-N C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C(N=1)=CSC=1C1=CC=CC(Cl)=C1 Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C(N=1)=CSC=1C1=CC=CC(Cl)=C1 UCJPHVSPOPXDQD-YCRPNKLZSA-N 0.000 claims 1
- GQMGUCKJKKNWKQ-IFXJQAMLSA-N C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC(OC)=CC=C1C(F)(F)F Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C1=CC(OC)=CC=C1C(F)(F)F GQMGUCKJKKNWKQ-IFXJQAMLSA-N 0.000 claims 1
- FYYBHDRKMUTTLO-MGPUTAFESA-N C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C=1C=NN(C)C=1OCCCC Chemical compound C1([C@]2(CC[C@@](C1=C1)(C2(C)C)[H])C)=NN=C1C=1C=NN(C)C=1OCCCC FYYBHDRKMUTTLO-MGPUTAFESA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- AGYHCOUSPPAYRK-UHFFFAOYSA-N ctk3h5409 Chemical compound CC1=CC(C)=CC=C1C(N=N1)=CC2=C1C1CCC2C1 AGYHCOUSPPAYRK-UHFFFAOYSA-N 0.000 claims 1
- ZCBLDDMNAGSYSF-UHFFFAOYSA-N ctk3h5410 Chemical compound ClC1=CC=CC(C=2N=NC=3C4CCC(C4)C=3C=2)=C1Cl ZCBLDDMNAGSYSF-UHFFFAOYSA-N 0.000 claims 1
- PSCJVXMIVNRVDV-UHFFFAOYSA-N ctk3h5413 Chemical compound ClC1=CC=C(Cl)C(C=2N=NC=3C4CCC(C4)C=3C=2)=C1 PSCJVXMIVNRVDV-UHFFFAOYSA-N 0.000 claims 1
- ILKLPNMCKNBYCN-UHFFFAOYSA-N ctk3h5416 Chemical compound C1CCC1C(N=N1)=CC2=C1C1CCC2C1 ILKLPNMCKNBYCN-UHFFFAOYSA-N 0.000 claims 1
- ONEVACYXCDIFJJ-UHFFFAOYSA-N ctk3h5417 Chemical compound FC(F)(F)OC1=CC=CC=C1C(N=N1)=CC2=C1C1CCC2C1 ONEVACYXCDIFJJ-UHFFFAOYSA-N 0.000 claims 1
- LHBYQRNLESZUBD-UHFFFAOYSA-N ctk3h5419 Chemical compound CC1=CC(F)=CC=C1C(N=N1)=CC2=C1C1CCC2C1 LHBYQRNLESZUBD-UHFFFAOYSA-N 0.000 claims 1
- FYHFMMDRLNNPFE-UHFFFAOYSA-N ctk3h5423 Chemical compound CC1=CC=CC=C1C(N=N1)=CC2=C1C1CCC2C1 FYHFMMDRLNNPFE-UHFFFAOYSA-N 0.000 claims 1
- VYKMDCCFASVTHE-UHFFFAOYSA-N ctk3h5427 Chemical compound C1CC1C(N=N1)=CC2=C1C1CCC2C1 VYKMDCCFASVTHE-UHFFFAOYSA-N 0.000 claims 1
- YSQRYCXWFFRMQW-UHFFFAOYSA-N ctk3h5440 Chemical compound FC1=CC=CC=C1C(N=N1)=CC2=C1C1CCC2C1 YSQRYCXWFFRMQW-UHFFFAOYSA-N 0.000 claims 1
- IKMXDQJPWLSNMH-UHFFFAOYSA-N ctk3h5441 Chemical compound FC1=CC(F)=CC=C1C(N=N1)=CC2=C1C1CCC2C1 IKMXDQJPWLSNMH-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05106098 | 2005-07-05 | ||
| PCT/EP2006/063533 WO2007003521A2 (en) | 2005-07-05 | 2006-06-26 | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110808T1 true HRP20110808T1 (hr) | 2011-12-31 |
Family
ID=36781523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110808T HRP20110808T1 (hr) | 2005-07-05 | 2011-11-02 | Derivati piridazina |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7678795B2 (ru) |
| EP (1) | EP1904455B1 (ru) |
| JP (1) | JP4787321B2 (ru) |
| KR (1) | KR100979582B1 (ru) |
| CN (1) | CN101528713B (ru) |
| AR (1) | AR054814A1 (ru) |
| AT (1) | ATE520670T1 (ru) |
| AU (1) | AU2006265201C1 (ru) |
| BR (1) | BRPI0613565A2 (ru) |
| CA (1) | CA2612740C (ru) |
| CL (1) | CL2009001936A1 (ru) |
| CR (1) | CR9587A (ru) |
| CY (1) | CY1112401T1 (ru) |
| DK (1) | DK1904455T3 (ru) |
| EC (1) | ECSP088082A (ru) |
| ES (1) | ES2370039T3 (ru) |
| HK (1) | HK1134087A1 (ru) |
| HR (1) | HRP20110808T1 (ru) |
| IL (1) | IL188182A (ru) |
| MA (1) | MA29909B1 (ru) |
| MX (1) | MX2007016352A (ru) |
| MY (1) | MY144209A (ru) |
| NO (1) | NO20076431L (ru) |
| NZ (1) | NZ564260A (ru) |
| PL (1) | PL1904455T3 (ru) |
| PT (1) | PT1904455E (ru) |
| RS (1) | RS51994B (ru) |
| RU (1) | RU2401832C2 (ru) |
| SI (1) | SI1904455T1 (ru) |
| TW (1) | TWI323258B (ru) |
| UA (1) | UA94052C2 (ru) |
| WO (1) | WO2007003521A2 (ru) |
| ZA (1) | ZA200710972B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834178B2 (en) | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| KR20090047458A (ko) | 2006-08-08 | 2009-05-12 | 사노피-아벤티스 | 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
| US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
| US20100022572A1 (en) | 2008-07-18 | 2010-01-28 | Kowa Company, Ltd. | Novel spiro compound and medicine comprising the same |
| JP5574431B2 (ja) | 2008-08-29 | 2014-08-20 | 興和株式会社 | １−アダマンチルアゼチジン−２−オン誘導体及びこれを含有する医薬 |
| JP5477973B2 (ja) | 2008-10-29 | 2014-04-23 | 興和株式会社 | １，２−ジアゼチジン−３−オン誘導体及びこれを含有する医薬 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| KR20160070162A (ko) * | 2013-11-05 | 2016-06-17 | 에프. 호프만-라 로슈 아게 | 자가면역 질병의 치료를 위한 RORc 조절인자로서 5,6,7,8-테트라하이드로-5,8-메타노신놀린 유도체 |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| BR112019008821A8 (pt) * | 2016-11-01 | 2020-02-04 | Hoffmann La Roche | derivados de piridazina como moduladores de rorc |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162859A0 (en) * | 2002-02-05 | 2005-11-20 | Novo Nordisk As | Novel aryl-and heteroarylpiperazines |
| TWI314455B (en) * | 2002-12-10 | 2009-09-11 | Nippon Kayaku Kk | 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| ATE455547T1 (de) * | 2003-04-11 | 2010-02-15 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen |
-
2006
- 2006-06-26 CN CN200680023527XA patent/CN101528713B/zh not_active Expired - Fee Related
- 2006-06-26 KR KR1020087000144A patent/KR100979582B1/ko not_active IP Right Cessation
- 2006-06-26 SI SI200631140T patent/SI1904455T1/sl unknown
- 2006-06-26 RS RS20110396A patent/RS51994B/en unknown
- 2006-06-26 EP EP06777461A patent/EP1904455B1/en active Active
- 2006-06-26 CA CA2612740A patent/CA2612740C/en not_active Expired - Fee Related
- 2006-06-26 JP JP2008519896A patent/JP4787321B2/ja not_active Expired - Fee Related
- 2006-06-26 AT AT06777461T patent/ATE520670T1/de active
- 2006-06-26 AU AU2006265201A patent/AU2006265201C1/en not_active Ceased
- 2006-06-26 ES ES06777461T patent/ES2370039T3/es active Active
- 2006-06-26 PL PL06777461T patent/PL1904455T3/pl unknown
- 2006-06-26 PT PT06777461T patent/PT1904455E/pt unknown
- 2006-06-26 MX MX2007016352A patent/MX2007016352A/es active IP Right Grant
- 2006-06-26 NZ NZ564260A patent/NZ564260A/en not_active IP Right Cessation
- 2006-06-26 UA UAA200801149A patent/UA94052C2/ru unknown
- 2006-06-26 DK DK06777461.2T patent/DK1904455T3/da active
- 2006-06-26 BR BRPI0613565-0A patent/BRPI0613565A2/pt not_active IP Right Cessation
- 2006-06-26 WO PCT/EP2006/063533 patent/WO2007003521A2/en active Application Filing
- 2006-06-26 RU RU2008103483/04A patent/RU2401832C2/ru not_active IP Right Cessation
- 2006-07-03 MY MYPI20063158A patent/MY144209A/en unknown
- 2006-07-03 AR ARP060102856A patent/AR054814A1/es not_active Application Discontinuation
- 2006-07-03 TW TW095124178A patent/TWI323258B/zh active
- 2006-07-05 US US11/481,330 patent/US7678795B2/en not_active Expired - Fee Related
-
2007
- 2007-12-11 CR CR9587A patent/CR9587A/es unknown
- 2007-12-14 NO NO20076431A patent/NO20076431L/no not_active Application Discontinuation
- 2007-12-17 IL IL188182A patent/IL188182A/en not_active IP Right Cessation
- 2007-12-18 ZA ZA200710972A patent/ZA200710972B/xx unknown
-
2008
- 2008-01-04 EC EC2008008082A patent/ECSP088082A/es unknown
- 2008-01-04 MA MA30542A patent/MA29909B1/fr unknown
-
2009
- 2009-10-06 CL CL2009001936A patent/CL2009001936A1/es unknown
-
2010
- 2010-02-25 HK HK10101976.4A patent/HK1134087A1/xx not_active IP Right Cessation
-
2011
- 2011-09-28 CY CY20111100942T patent/CY1112401T1/el unknown
- 2011-11-02 HR HR20110808T patent/HRP20110808T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110808T1 (hr) | Derivati piridazina | |
| JP2009500370A5 (ru) | ||
| EP2754660B1 (de) | Pyridazinonderivate | |
| KR101641596B1 (ko) | Ｐａｒｐ 억제제로서의 피리다지논 유도체 | |
| Dubey et al. | Pyridazinone: an important element of pharmacophore possessing broad spectrum of activity | |
| US7262202B2 (en) | Inhibitors of cyclin dependent kinases as anti-cancer agent | |
| HRP20050601A2 (en) | Chk-, pdk-, and akt-inhibitory pyrimidines, their production and use as pharmarmaceutical agents | |
| ZA200406225B (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | |
| CA2642211A1 (en) | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases | |
| WO2002051442A1 (fr) | Co-prescriptions | |
| WO2009029617A1 (en) | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors | |
| CA2671982A1 (en) | Methods of using mek inhibitors | |
| ZA200304671B (en) | Pyridaxinone aldose reductase inhibitors. | |
| MA30360B1 (fr) | Dérivés pyrimidiniques utilisés comme inhibiteurs de la pi3k | |
| EP2702043A1 (en) | Inhibitors of inducible form of 6-phosphofructose-2-kinase | |
| CA2655692A1 (en) | Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1) | |
| AU2002249389A1 (en) | Inhibitors of cyclin dependent kinases as anti-cancer agent | |
| CN1423646A (zh) | 作为抗炎/镇痛剂的杂环－烷基磺酰基吡唑衍生物 | |
| WO2016160938A1 (en) | N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators | |
| Hudkins et al. | Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity | |
| CN101501007B (zh) | 喹唑啉衍生物 | |
| CN101478989A (zh) | 炎性肠病的处置剂 | |
| CN101166529B (zh) | 作为大麻素受体拮抗剂的苯并三唑衍生物 | |
| Gao et al. | Benzofuran-isatin hybrids tethered via different length alkyl linkers and their in vitro anti-mycobacterial activities | |
| ZA200503959B (en) | 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands |